innerbuddies gut microbiome testing

Gut Microbiome & Inflammaging: How Your Microbes Drive Healthy Aging

Inflammaging—the chronic, low-grade inflammation that tends to rise with age—doesn’t happen in isolation. A key driver is the gut microbiome: the trillions of microbes that help regulate digestion, metabolism, and immune signaling. When the microbial ecosystem becomes less diverse or its balance shifts, it can tilt your immune system toward an inflammatory “always-on” state, increasing the risk of age-related decline.

Your gut microbes influence inflammaging through several interconnected pathways. They produce beneficial metabolites (like short-chain fatty acids) that help strengthen the gut lining and calm immune responses. At the same time, an imbalance can increase gut permeability (“leaky gut”), allowing inflammatory triggers to cross into the body and activating inflammatory pathways. This immune imbalance can also reduce how effectively your body resolves inflammation and returns to homeostasis.

The good news: because the microbiome is responsive, you can support healthier aging by nurturing it. Diet patterns rich in fiber, fermented foods, and polyphenols can promote beneficial microbes and their anti-inflammatory byproducts, while lifestyle factors like stress and poor sleep can disrupt microbial balance and worsen inflammatory signaling. By understanding how your gut microbes shape immune balance, you can target the roots of inflammaging and build a stronger foundation for long-term vitality.

Take the Gut Microbiome Test to Target Inflammaging—Check Your Results Get Your Gut Microbiome Test Subscription
innerbuddies gut microbiome testing

Inflammaging

Inflammaging is a chronic, low-grade inflammatory state that tends to rise with age, even without an overt infection. The gut microbiome is a major driver: age‑related dysbiosis reduces anti‑inflammatory, beneficial microbes and shifts metabolites away from immune‑tuning signals, weakening gut barrier and sustaining inflammatory signaling. Increased gut permeability allows bacterial components like LPS to enter circulation, while lower production of SCFAs such as butyrate impairs barrier integrity and immune regulation.

Typical microbial changes accompany inflammaging. Beneficial, SCFA‑producing taxa (e.g., Faecalibacterium prausnitzii, Roseburia, Eubacterium rectale, Anaerostipes, Akkermansia muciniphila, Bifidobacterium spp.) often decline, while pro‑inflammatory taxa (e.g., Escherichia/Shigella, Enterococcus, Streptococcus, Desulfovibrio, Bilophila wadsworthia, Ruminococcus gnavus) may rise. Mechanistically, reduced SCFA production weakens barrier defense and tolerance, and altered bile acid metabolism and immune training further promote a pro‑inflammatory baseline, contributing to fatigue, infections, digestive symptoms, and mucosal or skin inflammation.

Testing the gut microbiome can reveal patterns linked to inflammaging, guiding targeted lifestyle and dietary changes to restore diversity, boost SCFA production, and strengthen barrier function. Practical steps include higher dietary fiber, polyphenol‑rich plants, minimally processed foods, and appropriate use of probiotics or prebiotics. Tools like InnerBuddies aim to translate microbiome findings into personalized actions, connecting results to common symptoms and enabling data‑driven adjustments to reduce chronic immune activation over time.

  • Mechanism: Decline of SCFA-producing anti-inflammatory taxa (Faecalibacterium prausnitzii, Roseburia spp., Eubacterium rectale, Anaerostipes spp.) reduces butyrate, weakens gut barrier, and sustains inflammaging.
  • Mechanism: Loss of mucus- and barrier-supporting taxa (Akkermansia muciniphila; Bifidobacterium longum group; Bifidobacterium adolescentis) diminishes mucosal integrity and tolerogenic signaling.
  • Mechanism: Expansion of pro-inflammatory/endotoxin-producing taxa (Escherichia/Shigella; Enterococcus; Streptococcus; Ruminococcus gnavus group; Desulfovibrio; Bilophila wadsworthia; enterotoxigenic Bacteroides fragilis) increases LPS exposure and mucosal inflammation.
  • Mechanism: Dysbiosis-driven increased gut permeability leads to LPS translocation and activation of innate immunity (NF-κB, TLRs).
  • Mechanism: Altered microbial bile acid metabolism/signaling (FXR/TGR5) from dysbiosis promotes a pro-inflammatory baseline, with bile-acid–responsive taxa such as Bilophila wadsworthia and Desulfovibrio contributing.
  • Mechanism: Impaired immune training and reduced regulatory T cell induction due to loss of regulatory taxa (Faecalibacterium prausnitzii; Bacteroides fragilis), tipping toward chronic inflammation.
Take the Gut Microbiome Test to Target Inflammaging—Check Your Results Get Your Gut Microbiome Test Subscription
innerbuddies gut microbiome testing

Healthy aging / longevity-oriented topics

Inflammaging refers to the chronic, low-grade inflammatory state that tends to rise with age—even in the absence of an overt infection or disease. A major driver of this process is the gut microbiome. As we age, shifts in microbial diversity and balance (often termed “dysbiosis”) can reduce beneficial, anti-inflammatory species and increase microbes or microbial byproducts that promote immune activation. This can help explain why immune cells become more reactive and why inflammation can persist longer, contributing to age-related decline in tissue function.

The gut can influence inflammaging through several interconnected pathways. When the intestinal barrier becomes more permeable, bacterial components such as lipopolysaccharide (LPS) may cross into circulation, triggering inflammatory signaling (e.g., via innate immune sensors). In parallel, the microbiome produces metabolites—like short-chain fatty acids (SCFAs) including butyrate—that help regulate immune balance, support tight junction integrity, and calm inflammatory pathways. A microbiome that shifts away from SCFA-producing profiles can therefore weaken gut barrier defenses and reduce “immune-tuning” signals, leaving the body more prone to sustained inflammation.

Research also links gut microbial activity to immune aging (“immunosenescence”) and systemic inflammation by shaping how the body responds to antigens and maintains tolerance. Practical microbiome-support strategies—such as increasing dietary fiber to feed beneficial fermenters, emphasizing polyphenol-rich plants, choosing minimally processed foods, and using probiotic or prebiotic approaches when appropriate—may help reinforce a healthier microbial ecosystem. By improving microbial diversity, enhancing SCFA production, and strengthening gut barrier function, you can better support immune homeostasis and potentially mitigate the intensity or trajectory of inflammaging, promoting healthier long-term vitality.

  • Chronic low-grade inflammation (elevated inflammatory markers such as CRP)
  • Digestive discomfort (bloating, gas, abdominal pain or irregular stools)
  • Increased gut permeability (“leaky gut”) symptoms such as food sensitivities or post-meal discomfort
  • Frequent infections or slower recovery (immune imbalance)
  • Fatigue and reduced energy despite adequate rest
  • Unintentional weight changes or difficulty maintaining healthy weight
  • Skin and mucosal inflammation (acne, eczema flares, oral ulcers)
Take the Gut Microbiome Test to Target Inflammaging—Check Your Results Get Your Gut Microbiome Test Subscription
innerbuddies gut microbiome testing

Inflammaging

This is especially relevant for adults who notice signs of chronic low-grade inflammation as they age—such as persistently elevated markers (e.g., CRP), feeling “inflamed” most days, or experiencing fatigue and reduced energy despite adequate sleep. It may also fit people who suspect their immune system is staying activated longer than it should, leading to slower recovery from minor illnesses or a tendency toward frequent infections.

It’s also a good fit for individuals with gut-related symptoms that can point to microbiome imbalance and impaired barrier function, including bloating, gas, abdominal discomfort, or irregular stools. If you experience post-meal discomfort, food sensitivities, or symptoms that seem linked to digestion (sometimes described as “leaky gut”), the gut–immune connection described in inflammaging may be particularly relevant.

This approach is additionally relevant for anyone dealing with skin and mucosal inflammation (such as acne, eczema flares, or oral ulcers), as well as unintended weight changes or difficulty maintaining healthy weight. If your diet is often low in fiber and polyphenol-rich plants, or you rely heavily on highly processed foods and limited fermented/prebiotic options, supporting a healthier gut microbiome may help reinforce immune balance and reduce the likelihood that gut-driven inflammation continues over time.

“Inflammaging” is not a single diagnosable disease, so prevalence is usually described indirectly—by how commonly chronic low-grade inflammation and age-associated biomarker elevations appear in older adults. For example, age-related elevations in markers like high-sensitivity C-reactive protein (hs-CRP) are common: population studies frequently report that a substantial proportion of adults—often around 20–50% depending on the threshold used—have hs-CRP values consistent with low-grade systemic inflammation, and the proportion tends to rise steadily with age.

Because inflammaging is tightly linked to gut microbiome-driven immune activation, gut symptoms that often co-occur with this phenotype are also relatively common in aging populations. Digestive complaints such as bloating and altered stool patterns (including constipation or diarrhea) are frequently reported across community surveys, with estimates often in the broad range of roughly 10–30% of adults depending on definitions and whether functional GI disorders are included. Similarly, higher rates of immune imbalance (e.g., more frequent infections or slower recovery) are common with age, reflecting immunosenescence alongside persistent inflammatory signaling.

Markers suggestive of gut barrier dysfunction and mucosal inflammation—reported as “leaky gut” type symptoms (post-meal discomfort, food sensitivities) and chronic inflammatory skin/mucosal issues (eczema flares, acne, oral ulcers)—also appear more often with age and in people with chronic inflammatory phenotypes. While exact “inflammaging” percentages aren’t captured in clinical statistics, the overlap of elevated inflammatory markers (often measured in a large fraction of older adults), alongside common GI and mucosal inflammatory complaints (commonly reported by roughly 10–30% of adults for GI discomfort and a significant minority for inflammatory skin conditions), indicates that inflammaging is widespread and increasingly prevalent as people get older.

Take the Gut Microbiome Test to Target Inflammaging—Check Your Results Get Your Gut Microbiome Test Subscription
innerbuddies gut microbiome testing

Gut Microbiome & Inflammaging: How Your Microbes Drive Healthy Aging

Inflammaging is the chronic, low-grade inflammatory state that commonly increases with age, and the gut microbiome is a key contributor to this process. With aging, microbial diversity often declines and dysbiosis can shift the balance away from anti-inflammatory, beneficial microbes while increasing organisms and byproducts that stimulate immune activation. As a result, immune cells can become more reactive and inflammation may persist longer than it should, contributing to age-related decline.

A major gut-driven mechanism involves the intestinal barrier. When the gut lining becomes more permeable, bacterial components such as lipopolysaccharide (LPS) can enter circulation and trigger inflammatory signaling through innate immune pathways. At the same time, a less favorable microbiome may produce fewer immunoregulatory metabolites—especially short-chain fatty acids (SCFAs) like butyrate—that normally support tight junction integrity, help maintain gut barrier function, and “train” immune responses toward balance rather than chronic activation.

These microbiome-related shifts often show up as digestive and systemic symptoms. People may experience bloating, gas, abdominal discomfort, irregular stools, or food sensitivities associated with altered permeability and dysregulated tolerance. Ongoing immune imbalance can also contribute to fatigue, slower recovery from infections, and sometimes skin or mucosal inflammation such as acne, eczema flares, or oral ulcers—reflecting the gut–immune connection that underlies inflammaging.

Take the Gut Microbiome Test to Target Inflammaging—Check Your Results Get Your Gut Microbiome Test Subscription
innerbuddies gut microbiome testing

Gut Microbiome and Inflammaging

  • Gut dysbiosis with age: reduced microbial diversity and loss of beneficial, anti-inflammatory taxa increases pro-inflammatory immune stimulation.
  • Increased intestinal permeability (“leaky gut”): dysbiosis and epithelial stress weaken tight junctions, allowing bacterial components (e.g., LPS) to access circulation and trigger innate immune activation.
  • Reduced SCFA (e.g., butyrate) production: fewer immunoregulatory metabolites impair mucus/tight-junction integrity and reduce signaling that normally limits chronic inflammation.
  • Innate immune overactivation via microbial products: higher exposure to pathogen-associated molecules (LPS, peptidoglycan, flagellin) sustains NF-κB/TRL-mediated inflammatory pathways.
  • Impaired immune training and Treg balance: a less supportive microbiome decreases regulatory T cell induction and tolerance, increasing cytokines that drive chronic low-grade inflammation.
  • Altered bile acid metabolism: dysbiosis can shift bile acid pools toward less FXR/TGR5-activating, more pro-inflammatory signaling, affecting barrier function and systemic inflammation.
  • Mucosal immune dysregulation and chronic antigen exposure: persistent low-level microbial translocation and altered antigen handling can prolong inflammatory responses and slow resolution.

Inflammaging is a chronic, low-grade inflammatory state that often rises with age, and the gut microbiome plays a central role in shaping this immune baseline. As people get older, gut microbial diversity commonly declines and dysbiosis becomes more likely—shifting the balance away from beneficial, anti-inflammatory microbes toward communities that promote immune activation. This change can increase exposure of the immune system to microbial molecules while also reducing the signals that normally keep inflammation in check.

A key gut-driven mechanism involves intestinal barrier integrity. With age-related dysbiosis, epithelial stress and weakened tight junctions can increase gut permeability (“leaky gut”). When the barrier becomes more permeable, bacterial components such as LPS can reach circulation and stimulate innate immune pathways (including NF-κB and Toll-like receptors), reinforcing inflammatory signaling over time. At the same time, an unfavorable microbiome often produces less of crucial immunoregulatory metabolites—particularly short-chain fatty acids like butyrate—which help maintain mucus and tight junction structure and support immune tolerance rather than chronic activation.

Beyond barrier effects, altered microbial metabolism and immune training further sustain inflammation. Reduced SCFA production and changes in bile acid metabolism can impair regulatory signaling (e.g., less FXR/TGR5 activation) and contribute to a more pro-inflammatory immune environment. In addition, chronic low-level microbial exposure can dysregulate mucosal antigen handling and tipping of immune balance (including reduced Treg induction and tolerance), prolonging cytokine production and slowing inflammatory resolution. Together, these gut–immune feedback loops help explain why age-associated dysbiosis can manifest not only systemically (fatigue, slower recovery) but also through digestive symptoms and mucosal or skin inflammation.

Take the Gut Microbiome Test to Target Inflammaging—Check Your Results Get Your Gut Microbiome Test Subscription
innerbuddies gut microbiome testing

Microbial patterns summary

In inflammaging, aging is often accompanied by a gradual shift in gut microbial composition toward less diversity and greater dysbiosis. Beneficial, anti-inflammatory taxa and balanced communities that support mucosal health may decline, while organisms better suited to stress, inflammation, or altered nutrient availability can expand. This compositional shift is frequently linked to higher microbial product exposure to the immune system, increasing the baseline tendency for innate immune activation rather than efficient resolution.

A central microbial pattern involves reduced production of immunoregulatory metabolites—especially short-chain fatty acids such as butyrate—along with changes in microbial metabolic outputs that normally help maintain barrier integrity. When SCFA-generating populations decrease, tight junction and mucus support can weaken, which promotes intestinal permeability. As barrier function deteriorates, microbial components like lipopolysaccharide (LPS) are more likely to translocate across the gut lining and stimulate inflammatory signaling pathways, reinforcing chronic low-grade cytokine activity.

Beyond metabolism and barrier effects, dysbiosis can alter immune training and tolerance in the gut-associated lymphoid tissue. Microbiome-driven changes in antigen handling and signaling tone can reduce the induction of regulatory T cells and weaken tolerogenic pathways that normally dampen inflammation. In parallel, shifts in bile acid metabolism and related host–microbe signaling (including pathways influenced by microbial metabolites) may further favor a pro-inflammatory immune baseline, sustaining inflammatory persistence and contributing to systemic symptoms alongside digestive disturbances and mucosal or skin inflammation.


Low beneficial taxa

  • Faecalibacterium prausnitzii (butyrate producer)
  • Roseburia spp. (butyrate-producing; supports epithelial/anti-inflammatory signaling)
  • Eubacterium rectale (butyrate-producing; gut barrier and Treg support)
  • Anaerostipes spp. (butyrate producers; acetate/SCFA cross-feeding)
  • Akkermansia muciniphila (mucin-degrading; associated with mucus layer maintenance)
  • Bifidobacterium longum group (immunomodulatory; promotes tolerogenic responses)
  • Bifidobacterium adolescentis (SCFA and barrier-supporting, anti-inflammatory signaling)
  • Bacteroides (notably Bacteroides fragilis—enterotoxigenic strains excluded) (supports regulatory immune tone via microbial products)


Elevated / overrepresented taxa

  • Escherichia/Shigella (E. coli–like; endotoxin producers—often higher in dysbiosis)
  • Enterococcus (incl. Enterococcus faecalis; pro-inflammatory potential)
  • Streptococcus (oral-type lactic acid bacteria; often linked with gut overgrowth)
  • Bacteroides (dysbiosis-associated species/strains, incl. enterotoxigenic B. fragilis—ETBF exclusion noted for beneficial context)
  • Ruminococcus gnavus group (mucus-associated, pro-inflammatory carbohydrate metabolism)
  • Desulfovibrio (sulfate-reducing; can increase mucosal stress/inflammation)
  • Bilophila wadsworthia (bile-acid–responsive, pro-inflammatory associations)


Functional pathways involved

  • Short-chain fatty acid (SCFA) biosynthesis and butyrate/acetate cross-feeding—loss of immunoregulatory metabolites and weaker epithelial barrier support
  • Intestinal barrier integrity and mucus/tight-junction maintenance—microbe-driven regulation of mucin homeostasis, antimicrobial peptides, and epithelial tight junctions
  • Microbial product translocation and innate immune activation (e.g., LPS/endotoxin trafficking)—increased baseline NF-κB/TLR signaling and chronic low-grade inflammation
  • Treg induction and immune tolerance programming in gut-associated lymphoid tissue—reduced microbiome-driven tolerogenic signaling and regulatory immune tone
  • Microbial bile acid metabolism and host–microbe signaling (FXR/TGR5 axis)—dysregulated bile acids promoting pro-inflammatory immune bias
  • Mucus-associated carbohydrate fermentation and mucin utilization—shift toward pro-inflammatory energy harvest and reduced protective mucus-layer stability
  • Redox/sulfide stress pathways (sulfate reduction to hydrogen sulfide; Desulfovibrio-linked metabolites)—increased oxidative/mucosal stress and inflammatory persistence


Diversity note

In inflammaging, aging is often accompanied by a gradual decline in gut microbial diversity, with a shift toward a less balanced community (dysbiosis). This can mean fewer beneficial, barrier-supporting and anti-inflammatory taxa, alongside an increase in organisms that thrive under stress or altered nutrient conditions. As diversity drops, the ecosystem becomes less resilient—so minor dietary or lifestyle changes can more easily tip the microbiome toward states that promote ongoing immune activation rather than efficient resolution.

A common diversity-related pattern involves reduced output of immunoregulatory microbial metabolites, particularly short-chain fatty acids (SCFAs) like butyrate. SCFAs help support tight junction integrity, mucus production, and the immune “training” processes that normally encourage tolerance. When SCFA-producing populations decrease, gut barrier function may weaken, increasing intestinal permeability and making it easier for inflammatory microbial components (such as LPS) to reach circulation and stimulate innate immune pathways.

These compositional and metabolic shifts also affect gut immune signaling, including regulatory pathways in gut-associated lymphoid tissue. With a less diverse microbiome, tolerogenic signals can be blunted—such as the reduced induction of regulatory T cells—while pro-inflammatory signaling tone becomes more persistent. In parallel, changes in microbial metabolism (including bile acid–related signaling) can further bias immune responses toward a chronic low-grade inflammatory baseline, contributing to the digestive symptoms and systemic inflammation often seen with age.


Take the Gut Microbiome Test to Target Inflammaging—Check Your Results Get Your Gut Microbiome Test Subscription

Why generic solutions fail

  • Issue with generic solutions

    Generic solutions for inflammaging often fail because they don’t address the specific gut-microbiome dynamics that drive chronic low-grade inflammation. In many older adults, inflammaging is tied to age-related dysbiosis—typically lower microbial diversity and a shift away from butyrate- and SCFA-producing taxa. Simply “adding probiotics” or broad-spectrum antimicrobial approaches may not restore the metabolic outputs (especially SCFAs) that support mucus integrity and tight junction stability, so intestinal permeability can remain elevated and immune activation continues.

    They also frequently miss the barrier–immune feedback loop that sustains inflammation. When the gut lining becomes more permeable, microbial components like LPS can cross into circulation and repeatedly stimulate innate immune signaling. Generic gut supplements may improve symptoms temporarily (e.g., bloating or stool form) without sufficiently reducing the underlying drivers of barrier dysfunction, such as diminished microbial metabolite signaling, altered bile acid metabolism, and reduced immune tolerogenic signaling in gut-associated lymphoid tissue.

    Finally, one-size-fits-all strategies often fail to consider individual variability in baseline diet, medications (like proton pump inhibitors, metformin, or NSAIDs), fiber intake, and existing sensitivities. If someone’s microbiome is skewed toward organisms that promote pro-inflammatory immune tone or has low capacity for SCFA production, a generic plan won’t reliably “train” regulatory pathways (e.g., Treg balance) or shift immune responsiveness toward resolution. The result is persistent dysbiosis-linked inflammatory signaling and ongoing digestive and systemic symptoms despite generalized interventions.

  • Common mistakes

    • Only targeting “bacteria counts” (e.g., adding generic probiotics) without restoring SCFA/butyrate-producing metabolic functions that support mucus and tight-junction integrity
    • Using broad-spectrum antimicrobials or “reset” strategies without considering that they may further reduce diversity and delay recovery of beneficial metabolite outputs (including SCFAs)
    • Failing to address the barrier–immune feedback loop (increased permeability → LPS/translocation → sustained innate immune activation), focusing only on symptom control (e.g., bloating) rather than root driver reduction
    • Ignoring host and context factors that shape the microbiome (baseline diet/fiber diversity, medication use such as PPIs, metformin, NSAIDs) and assuming the same intervention will work for everyone
    • Neglecting bile acid–microbiome signaling and not supporting the bile acid pathways that influence inflammation resolution (rather than only emphasizing fermentation fiber or general digestion support)
    • Not accounting for inter-individual tolerance/immune tone differences (e.g., reduced Treg induction, altered antigen handling), leading to plans that may not shift gut immune training toward regulation
    • Overlooking that low fiber or insufficient fermentable substrates can prevent SCFA recovery even if beneficial strains are introduced via supplements/foods
    • Measuring success with generic endpoints (stool form/frequency) while missing microbiome-function markers relevant to inflammaging (barrier support, inflammatory metabolite balance, permeability risk)

What to do

  • General support strategies

    Support for inflammaging with a gut-focused approach centers on restoring a healthier microbiome balance and strengthening intestinal barrier function. As microbial diversity declines with age, dysbiosis can increase gut-derived immune triggers while reducing beneficial organisms that produce anti-inflammatory compounds. Practical strategies therefore often emphasize dietary patterns that feed beneficial microbes (e.g., a high-fiber, plant-forward intake that increases prebiotic substrates), while limiting ultra-processed foods and excessive added sugars that can worsen dysbiosis. Consistently supporting a diverse microbial ecosystem can help shift immune activity away from chronic, low-grade activation.

    A second priority is improving gut barrier integrity so inflammatory bacterial components are less likely to cross into circulation. The barrier is supported in part by microbial metabolites—especially short-chain fatty acids (SCFAs) like butyrate—which help maintain tight junctions and support mucosal healing. Approaches that raise SCFA availability (through fiber/prebiotics and, when appropriate, targeted probiotic or fermented foods) may help reduce permeability-related immune signaling. In people with symptoms such as bloating, irregular stools, or food-triggered discomfort, strategies that address dysbiosis and gut sensitivity can indirectly reduce ongoing immune stimulation.

    Finally, because inflammaging is closely tied to immune regulation, strategies often aim to promote a more balanced immune response. This includes supporting adequate micronutrients involved in immune and mucosal function (such as vitamin D, zinc, and omega-3 fats), optimizing sleep and stress management (which can influence gut motility and immune tone), and correcting constipation or diarrhea patterns that can perpetuate microbial imbalance. When tolerated, individualized use of probiotics/prebiotics, fermented foods, and metabolite-supporting nutrition may help reinforce immune “training” toward tolerance, supporting systemic resilience and reducing the persistence of inflammation with age.

  • Lifestyle recommendations

    • Prioritize a fiber-rich, plant-forward diet (e.g., legumes, vegetables, whole grains) to support microbial diversity and increase beneficial SCFA producers like butyrate.
    • Include fermented foods regularly (e.g., yogurt/kefir, sauerkraut, kimchi) if tolerated to help rebalance the gut microbiome toward a more anti-inflammatory profile.
    • Limit ultra-processed foods, added sugars, and excess alcohol, which can promote dysbiosis and increase inflammatory signaling.
    • Support gut barrier function by staying well-hydrated, maintaining consistent meal timing, and managing common triggers that worsen symptoms (e.g., certain high-FODMAP foods for sensitive individuals).
    • Practice regular physical activity (and avoid prolonged sedentary time) to modulate immune function and improve gut microbial composition.
    • Prioritize adequate sleep and stress management (e.g., mindfulness, breathing exercises, CBT, or other relaxation practices) to reduce immune overactivation linked to inflammaging.
    • Consider individualized gut-focused interventions if symptoms persist—such as working with a clinician on elimination trials, checking for deficiencies (e.g., vitamin D), and evaluating for GI conditions (e.g., IBD, celiac, IBS) before self-treating.

  • Nutrition recommendations

    • Increase dietary fiber (aim for ~25–38 g/day) from diverse sources (vegetables, legumes, oats, chia/flax) to support microbial diversity and increase beneficial SCFA production (especially butyrate).
    • Prioritize prebiotic fibers and microbiome-supporting foods (inulin/oligofructose sources like chicory root, Jerusalem artichoke, garlic, onions, leeks, resistant starch like cooled potatoes/rice) in gradually increasing amounts.
    • Include daily fermented foods (e.g., yogurt/kefir with live cultures, sauerkraut, kimchi, tempeh, miso) to improve microbial balance and potentially dampen low-grade inflammation.
    • Support gut barrier function with omega-3 fats (fatty fish 2–3x/week or chia/flax/walnuts) and adequate protein (from fish, eggs, poultry, legumes) to reduce pro-inflammatory signaling.
    • Choose an anti-inflammatory dietary pattern: emphasize olive oil, colorful plants, nuts, seeds, and minimally processed foods; limit ultra-processed foods, added sugars, and refined carbs that can worsen dysbiosis.
    • Reduce endotoxin/LPS-promoting habits by avoiding excessive alcohol and limiting charred/grilled high-heat meats; choose gentler cooking methods where possible (steaming, stewing) to lower harmful byproducts.
    • Ensure micronutrient adequacy relevant to mucosal immunity and inflammation control (vitamin D, zinc, magnesium, selenium) via food-first choices and consider targeted supplementation only if labs suggest deficiency.
    • If symptoms include bloating/irregular stools, trial a temporary reduction of common triggers (e.g., high-FODMAP foods, lactose if intolerant) while increasing tolerated fibers, and consider guidance from a clinician or dietitian.

  • Supplement considerations

    For inflammaging, supplement strategies typically aim to reduce chronic low-grade immune activation while supporting the gut barrier and a healthier microbial ecosystem. Since age-associated dysbiosis can lower beneficial taxa and increase microbes or byproducts that stimulate innate immunity, ingredients that promote microbial diversity and immune regulation are often considered. Supportive approaches may include targeted probiotics or probiotic consortia, along with prebiotics (such as inulin-type fibers or resistant starch) that help feed beneficial microbes and increase production of immunomodulatory metabolites.

    A central gut link to inflammaging is intestinal permeability, where higher exposure to bacterial components like LPS can trigger pro-inflammatory signaling. Nutrients that help strengthen tight junctions and support mucus/epithelial integrity are therefore commonly prioritized. Butyrate-related support (direct butyrate or precursors that raise endogenous production), along with compounds like polyphenols (depending on formulation and tolerance), may contribute to barrier function and help shift immune signaling away from persistent activation. In parallel, antioxidants and cofactors involved in redox balance can be relevant because oxidative stress often amplifies inflammatory pathways during aging.

    Because dysregulated microbiome–immune communication can also show up as bloating, irregular stools, or food sensitivities, supplement choices should be individualized to tolerance and symptom pattern. Fermented or microbial-derived metabolites, well-studied strains with documented safety in older adults, and gut-friendly fiber strategies can be beneficial, but they may need gradual titration to avoid gas or discomfort. If there are signs of gut-driven systemic issues (e.g., frequent flares of skin/mucosal inflammation, fatigue, or persistent GI symptoms), it’s also worth considering whether additional support for bile flow, digestion, or targeted anti-inflammatory modulation is appropriate—ideally guided by a clinician, especially in people on immunosuppressants or with significant comorbidities.

  • Retesting / monitoring note

    For inflammaging, retesting is typically most useful when you’re tracking whether microbiome-driven inflammation and barrier stress are improving over time, rather than expecting immediate changes day-to-day. A common approach is to recheck key gut-linked markers after a defined intervention window—often around 8–12 weeks for diet and microbiome-targeted protocols—so results can reflect shifts in microbial diversity, dysbiosis, and gut permeability rather than short-lived variability. If multiple interventions are introduced, re-test after each phase or keep changes consistent until the retest to make trends easier to interpret.

    When planning what to retest, focus on indicators that map to the main mechanisms of inflammaging: gut barrier integrity, microbial dysbiosis, and downstream immune activation. Marker patterns that suggest reduced LPS-driven signaling (e.g., lower inflammatory readouts) alongside improved gut barrier function are particularly informative, as are stool-based metrics that reflect beneficial SCFA capacity (like butyrate-supporting microbial activity) and reduced inflammatory dysbiosis. Depending on your baseline results and symptoms, clinicians may pair stool microbiome and metabolite evaluation with blood-based inflammatory markers to confirm that changes in the gut environment correlate with systemic inflammation trends.

    Retesting frequency should also account for biological “noise” and symptom fluctuations. Stool composition can vary with recent meals, stress, sleep, medications, and illness, so standardizing sample collection (consistent diet in the days prior, avoiding antibiotics or gut-altering drugs when possible, and repeating if the first sample was taken during a flare) improves reliability. If results remain unchanged, it’s often better to review adherence and upstream drivers (fiber variety, protein source, alcohol intake, sleep and stress, and medication exposures) before repeating too soon; in such cases, a longer interval such as 12–16 weeks may be more informative to allow meaningful microbiome remodeling.

The importance of gut microbiome testing

  • Why testing matters

    Inflammaging is fueled in part by age-related shifts in the gut microbiome that can drive immune activation long before classic disease appears. Gut microbiome testing helps identify patterns like reduced microbial diversity, dysbiosis, and an overrepresentation of taxa or microbial byproducts associated with pro-inflammatory signaling. By mapping what’s happening in the gut ecosystem, testing can reveal whether your inflammation may be supported by microbiome imbalance rather than lifestyle or aging alone, making the “gut link” more actionable.

    A key mechanism behind inflammaging involves intestinal barrier function. When the gut lining becomes more permeable, molecules such as lipopolysaccharide (LPS) can more easily reach circulation and stimulate innate immune pathways. Microbiome testing can offer indirect clues about barrier-supporting capacity—particularly through the abundance of microbes that produce beneficial metabolites like short-chain fatty acids (SCFAs), including butyrate. Lower SCFA-supporting communities may correlate with weaker tight-junction maintenance and reduced immune regulation, helping explain why some people experience persistent low-grade inflammation.

    Testing also matters because it connects gut changes to real-world symptoms and treatment planning. Results can highlight fermentation and tolerance-related imbalances that often show up as bloating, gas, irregular stools, or food sensitivities, while also informing nutrition and probiotic/prebiotic strategy aimed at restoring immune balance. Instead of guessing, you can use test findings to target the microbiome components most likely contributing to your inflammatory tone—supporting more personalized, data-informed adjustments that may reduce chronic immune activation over time.

  • How InnerBuddies helps

    InnerBuddies helps with inflammaging by examining gut microbiome patterns that are closely linked to chronic, low-grade immune activation. Since aging often comes with reduced microbial diversity and dysbiosis, the test can reveal shifts in the balance of microbial communities—such as a relative underrepresentation of taxa associated with immune-regulating functions and an overrepresentation of patterns that may be more inflammatory. By identifying these ecosystem-level changes, InnerBuddies can clarify whether your inflammatory tone has a gut-driven component rather than being explained by aging or lifestyle alone.

    A major driver of inflammaging is intestinal barrier dysfunction, where bacterial components like lipopolysaccharide (LPS) can more easily reach the bloodstream and stimulate innate immune pathways. InnerBuddies can provide actionable insight into gut features that influence barrier support, including the microbiome’s potential to produce beneficial metabolites such as short-chain fatty acids (SCFAs) like butyrate. When SCFA-supporting communities are diminished, tight-junction maintenance and immune “education” may weaken—so the test can help connect your microbiome profile to the barrier-related mechanism behind ongoing inflammation.

    InnerBuddies also helps translate microbiome findings into practical next steps by linking results to common symptoms that often accompany gut-driven inflammaging, including bloating, gas, irregular stools, and food-related sensitivities. With the test, you can move beyond general recommendations and instead target the specific microbial imbalances suggested by your results, supporting stronger barrier function, improved tolerance, and more balanced immune signaling over time.

Medical Evidence

  • Scientific evidence level

    2 [weak / emerging, inconsistent; mechanistic rationale stronger than clinical-grade evidence]

  • Clinical relevance note

    At present, gut microbiome evidence for inflammaging is more consistent with a contributory/maintaining factor than a proven primary driver that can be reliably measured and targeted for clinical benefit. The strongest contribution is mechanistic plausibility and recurring observational links between dysbiosis/metabolite profiles and systemic inflammatory markers. Yet, the field lacks consistent, reproducible microbiome signatures tied to a clearly defined inflammaging phenotype, and most studies cannot rule out confounding (diet, medication—especially PPIs/antibiotics—comorbidities, socioeconomic factors, smoking, activity, frailty), nor adequately address reverse causality (inflammation altering gut ecology).

    Clinically, this means microbiome profiling is not validated for inflammaging management. Microbiome-targeted nutrition or supplements may influence some inflammatory biomarkers, but the current evidence does not establish durable, clinically meaningful changes in inflammaging-related outcomes, nor does it demonstrate that microbiome measurements improve patient stratification or monitoring beyond standard clinical biomarkers. Until larger, well-designed prospective cohorts using standardized sampling/assays and longer, adequately powered RCTs with clinically meaningful endpoints (and external validation of biomarker models) are available, clinical application should be considered hypothesis-generating rather than actionable.

Title Journal Year Link
Ageing and the gut microbiome: longitudinal effects, implications and interventions Cell Host & Microbe 2018 View →
Microbiota-induced inflammation and inflammaging: mechanisms and opportunities for therapeutic intervention Nature Reviews Immunology 2018 View →
Aging, inflammation, and the gut microbiota Trends in Microbiology 2017 View →
Gut microbiota and inflammaging: A new paradigm for healthy aging? Ageing Research Reviews 2017 View →
The gut microbiome in ageing and in age-related diseases Nature Reviews Microbiology 2016 View →

Frequently Asked Questions

    Qu'est‑ce que l'inflammaging et comment l'intestin est impliqué?
    L'inflammaging est un état inflammatoire chronique de faible intensité qui augmente avec l'âge. Le microbiome intestinal influence cela par la diversité, la barrière et les métabolites comme les SCFA (ex. le butyrate) qui régulent l'immunité.
    Qu'est‑ce que la barrière intestinale et pourquoi est‑elle importante pour l'inflammaging?
    La barrière intestinale empêche les microbes et leurs molécules de passer dans la circulation. Si elle devient plus perméable (« fuite intestinale »), des composants bactériens comme le LPS peuvent circuler et stimuler l'inflammation.
    Qu'est‑ce que les SCFA et le butyrate, et pourquoi sont‑ils importants?
    Les SCFA sont des métabolites produits par les bactéries intestinales; le butyrate est l'un des plus importants. Ils nourrissent l'épithélium, régulent l'immunité et renforcent la barrière; une diminution des producteurs de SCFA peut être associée à plus d'inflammation.
    Quels signes surveiller qui pourraient être liés à l'inflammaging?
    Marqueurs inflammatoires persistants (ex. hs‑CRP), troubles digestifs (ballonnements, gaz, selles irrégulières), signes de perméabilité intestinale (sensibilités alimentaires), fatigue, variations de poids et inflammation cutanée ou des muqueuses.
    À quelle fréquence l'inflammaging est‑il présent chez les personnes âgées?
    Ce n'est pas une maladie unique; beaucoup de seniors présentent des marqueurs inflammatoires élevés et des symptômes gastro‑intestinaux. Les estimations varient; une part significative a hs‑CRP élevé et des symptômes GI autour de 10–30%.
    Quels patrons de bactéries intestinales sont liés à l'inflammaging?
    Diminution des taxa bénéfiques producteurs de butyrate (Faecalibacterium prausnitzii, Roseburia, Eubacterium), Akkermansia muciniphila et Bifidobacterium; augmentation possible de taxa pro‑inflammatoires comme Escherichia/Shigella, Enterococcus, Desulfovibrio, Bilophila wadsworthia et Ruminococcus gnavus.
    Comment un test du microbiome peut‑il aider à l'inflammaging?
    Le test peut révéler des schémas de dysbiose, la diversité et l’abondance des producteurs de SCFA; les résultats peuvent guider l’alimentation, les probiotiques/prébiotiques et des stratégies pour soutenir la barrière et l’équilibre immunitaire.
    Que puis‑je faire au quotidien pour soutenir un microbiome plus sain?
    Adopter une alimentation riche en fibres et peu transformée, avec des plantes riches en polyphénols; inclure des aliments fermentés; envisager des probiotiques/prébiotiques ciblés sous supervision; bien s’hydrater; limiter les sucres ajoutés et les aliments ultra‑transformés.
    Existe‑t‑il des médicaments ou des compléments prouvés contre l'inflammaging?
    Il n’existe pas de remède démontré. L’approche privilégie le mode de vie et l’alimentation pour soutenir la santé intestinale; consulter un professionnel avant de commencer des compléments ou des tests.
    Quel rôle joue le LPS dans l'inflammaging?
    Le LPS est un composant bactérien qui peut traverser une barrière intestinale plus perméable et activer des voies inflammatoires.
    Comment le vieillissement modifie‑t‑il le microbiome (dysbiose)?
    Avec l’âge, la diversité diminue souvent et les taxa pro‑inflammatoires peuvent augmenter; les producteurs de SCFA diminuent, ce qui peut affaiblir la barrière et favoriser l’inflammation.
    Que fait InnerBuddies et comment peut‑il aider?
    InnerBuddies analyse les motifs du microbiome liés à l'inflammaging et signale les déséquilibres et les points d’attention; aide à discuter avec des professionnels et à orienter les changements de mode de vie; ce n’est pas un diagnostic.
    L'inflammaging peut‑il être inversé ou ralenti?
    Ce n’est pas une maladie, mais l’alimentation et la santé intestinale peuvent potentiellement réduire l’inflammation; les résultats varient et les changements à long terme prennent du temps.
    Combien de temps faut‑il pour voir des changements dans la santé intestinale après des changements de mode de vie?
    Les modifications du microbiome et des marqueurs inflammatoires peuvent prendre des semaines à des mois; la constance est clé.

    Hear from our satisfied customers!

    • "I would like to let you know how excited I am. We had been on the diet for about two months (my husband eats with us). We felt better with it, but how much better was really only noticed during the Christmas vacations when we had received a large Christmas package and didn't stick to the diet for a while. Well that did give motivation again, because what a difference in gastrointestinal symptoms but also energy in both of us!"

      - Manon, age 29 -

    • "Super help!!! I was already well on my way, but now I know for sure what I should and should not eat, drink. I have been struggling with stomach and intestines for so long, hope I can get rid of it now."

      - Petra, age 68 -

    • "I have read your comprehensive report and advice. Many thanks for that and very informative. Presented in this way, I can certainly move forward with it. Therefore no new questions for now. I will gladly take your suggestions to heart. And good luck with your important work."

      - Dirk, age 73 -